Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug

Takeda Pharmaceutical Co ( (JP:4502) ) has provided an update.

Takeda has had its New Drug Application for oveporexton (TAK-861), an oral orexin receptor 2-selective agonist for narcolepsy type 1, accepted by the U.S. Food and Drug Administration with Priority Review and a target action date in the third quarter of this year. The potential first-in-class therapy, backed by positive Phase 3 data showing clinically meaningful improvements across key NT1 symptoms and a generally well-tolerated safety profile, would strengthen Takeda’s leadership in orexin science, expand its orexin franchise alongside other pipeline candidates, and address a significant unmet need in a rare neurological disease without materially affecting its current-year financial forecast.

Narcolepsy type 1 is a chronic rare neurological disorder driven by orexin deficiency and marked by excessive daytime sleepiness and cataplexy, which significantly impairs patients’ daily functioning despite existing therapies. Oveporexton’s progress, supported by prior Breakthrough Therapy and other regulatory designations in major markets, positions Takeda to potentially reshape the treatment landscape for sleep-wake disorders and reinforces its strategic push into neuroscience through a differentiated portfolio of investigational orexin agonists for related conditions such as narcolepsy type 2 and idiopathic hypersomnia.

The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5792.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.

More about Takeda Pharmaceutical Co

Takeda Pharmaceutical Co. is a Japan-headquartered, values-based, R&D-driven biopharmaceutical company focused on developing life-transforming treatments across gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. With employees in about 80 countries and a broad pipeline, Takeda emphasizes partnerships to advance innovative therapies and improve patient outcomes globally.

Average Trading Volume: 4,970,385

Technical Sentiment Signal: Buy

Current Market Cap: Yen8744.3B

Find detailed analytics on 4502 stock on TipRanks’ Stock Analysis page.